Myeloma UK-funded researchers at The Institute of Cancer Research have published new research into how studying specific genetic abnormalities in myeloma cells to help create more targeted and effective treatments.
University Hospitals of North Midlands NHS Trust (UHNM) is the latest organisation to join the Myeloma UK Clinical Trial Network (CTN), which aims to help patients access the latest, innovative myeloma treatments.
Myeloma Awareness Week 2017 focuses is on early diagnosis because for patients, every day counts. Here’s how you can get involved!
Carfilzomib (Kyprolis®) has been approved for use on the NHS in England and Wales in combination with dexamethasone by drug approval body, the National Institute for Health and Care Excellence (NICE). The approval applies only to myeloma patients who have had one prior treatment, as long as that treatment did not include bortezomib, which is also known as Velcade®.
A recent case study has been published exploring a relapsing myeloma patient’s experience of taking curcumin as a complementary therapy […]
A new survey being funded by Myeloma UK and carried out by the National Institute for Health and Care Excellence […]
Myeloma UK has launched a new Infopack to provide relapsed and/or refractory patients and their families with the information they […]
Daratumumab (Darzalex®) has been granted an extended licence for use in combination with other myeloma drugs for the treatment of relapsed […]